IART Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Integra Lifesciences Holdings Corp (IART) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock's financial performance shows declining revenue, net income, and EPS, while technical indicators and trading sentiment do not suggest a compelling entry point. Additionally, there are no strong positive catalysts or proprietary trading signals to support an immediate purchase.
The MACD is positive but contracting, RSI is neutral at 40.931, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 11.526, with support at 10.848 and resistance at 12.204. Overall, the technical indicators suggest a lack of strong momentum in either direction.
The company exceeded analyst expectations for Q4 2025 revenue and adjusted EPS. Despite a slight revenue decline, the results were better than anticipated.
The company reported a significant year-over-year decline in net income (-108.77%) and EPS (-108.00%), with gross margin also dropping by 15.70%. Additionally, the stock has a 60% chance of declining by -1.47% in the next day and shows weak medium-term growth potential.
In Q4 2025, revenue declined by 1.74% YoY to $434.9 million. Net income dropped significantly to -$1.70 million from $19.44 million YoY. EPS fell to -$0.02, and gross margin decreased to 49.92%, reflecting operational challenges and declining profitability.
No recent updates on analyst ratings or price target changes were provided. Wall Street sentiment appears neutral based on the lack of significant trading trends among hedge funds and insiders.
